CN111108117B - 胰高血糖素样肽1受体激动剂及其用途 - Google Patents

胰高血糖素样肽1受体激动剂及其用途 Download PDF

Info

Publication number
CN111108117B
CN111108117B CN201880061327.6A CN201880061327A CN111108117B CN 111108117 B CN111108117 B CN 111108117B CN 201880061327 A CN201880061327 A CN 201880061327A CN 111108117 B CN111108117 B CN 111108117B
Authority
CN
China
Prior art keywords
glp1
ser
val
gly
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880061327.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN111108117A (zh
Inventor
魏阳
冈本悠
杰斯珀·格罗马达
塞缪尔·戴维斯
安德鲁·J·墨菲
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Priority to CN202410964216.3A priority Critical patent/CN118955732A/zh
Publication of CN111108117A publication Critical patent/CN111108117A/zh
Application granted granted Critical
Publication of CN111108117B publication Critical patent/CN111108117B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/082—Hepadnaviridae (F), e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
CN201880061327.6A 2017-09-22 2018-09-21 胰高血糖素样肽1受体激动剂及其用途 Active CN111108117B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410964216.3A CN118955732A (zh) 2017-09-22 2018-09-21 胰高血糖素样肽1受体激动剂及其用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762562283P 2017-09-22 2017-09-22
US62/562,283 2017-09-22
PCT/US2018/052110 WO2019060653A1 (en) 2017-09-22 2018-09-21 GLP-1 RECEPTOR AGONISTS (GLUCAGON-LIKE PEPTIDE 1) AND USES THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410964216.3A Division CN118955732A (zh) 2017-09-22 2018-09-21 胰高血糖素样肽1受体激动剂及其用途

Publications (2)

Publication Number Publication Date
CN111108117A CN111108117A (zh) 2020-05-05
CN111108117B true CN111108117B (zh) 2024-08-06

Family

ID=63799082

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880061327.6A Active CN111108117B (zh) 2017-09-22 2018-09-21 胰高血糖素样肽1受体激动剂及其用途
CN202410964216.3A Pending CN118955732A (zh) 2017-09-22 2018-09-21 胰高血糖素样肽1受体激动剂及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410964216.3A Pending CN118955732A (zh) 2017-09-22 2018-09-21 胰高血糖素样肽1受体激动剂及其用途

Country Status (14)

Country Link
US (4) US11045522B2 (https=)
EP (1) EP3684793A1 (https=)
JP (3) JP7239566B2 (https=)
KR (1) KR102696518B1 (https=)
CN (2) CN111108117B (https=)
AU (2) AU2018338178B2 (https=)
CA (1) CA3073964A1 (https=)
EA (1) EA202090649A1 (https=)
IL (2) IL304574B2 (https=)
MX (1) MX2020002977A (https=)
MY (2) MY200364A (https=)
SG (1) SG11202001637PA (https=)
WO (1) WO2019060653A1 (https=)
ZA (1) ZA202001167B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY200364A (en) * 2017-09-22 2023-12-21 Regeneron Pharma Glucagon-like peptide 1 receptor agonists and uses thereof
US12122817B2 (en) * 2020-09-22 2024-10-22 Serpentide Inc. Long-lasting GLP1 analogue drug for type-2 diabetes
JP7731596B2 (ja) * 2020-12-03 2025-09-01 イムノフォージ カンパニー リミテッド Ｇｌｐ－１受容体アゴニスト及び抗オスカー抗体を含む融合タンパク質及びその用途
WO2022117044A1 (en) * 2020-12-03 2022-06-09 Sunshine Lake Pharma Co., Ltd. Glp-1/gcg dual receptor agonist polypeptide and fusion protein thereof
CN112716966B (zh) * 2021-02-03 2022-05-03 浙江诺得药业有限公司 一种恩格列净药用组合物及其制备方法
CN113461785B (zh) * 2021-04-13 2022-10-14 湖南中晟全肽生化有限公司 Glp-1受体激动剂及其应用
CN119638849A (zh) * 2021-10-18 2025-03-18 深圳科兴药业有限公司 一种生长激素融合蛋白及其应用
CN114788876B (zh) * 2022-02-24 2024-07-05 北京医院 治疗糖尿病的mRNA药物制剂及其制备方法与应用
US20250289861A1 (en) * 2022-05-04 2025-09-18 Immunoforge Co.,Ltd. Fusion protein comprising glp-1, immunoglobulin fc, and igf-1 and use thereof
WO2024123812A1 (en) 2022-12-05 2024-06-13 Shattuck Labs, Inc. Fusion proteins for the treatment of cardiometabolic diseases
CN117143242B (zh) * 2023-10-30 2024-03-29 南京佰抗生物科技有限公司 抗Galectin-3蛋白的单克隆抗体组合物及应用
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
US20250270274A1 (en) * 2024-02-26 2025-08-28 Serpentide Inc. Super long-lasting glp1 or glp1/gip analogue drug for type-2 diabetes and obesity

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05013565A (es) 2003-06-12 2006-03-09 Lilly Co Eli Proteinas de fusion analogas al glp-1.
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US20060275288A1 (en) 2005-01-20 2006-12-07 Grihalde Nelson D GLP-1 receptor agonist and allosteric modulator monoclonal antibodies and uses thereof
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
TW200843794A (en) 2006-12-21 2008-11-16 Centocor Inc Use of long-acting GLP-1 receptor agonists to improve insulin sensitivity and lipid profiles
CA2693504A1 (en) 2007-08-03 2009-02-12 Eli Lilly And Company Treatment for obesity
EP2190872B1 (en) 2007-09-05 2018-03-14 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
US8748377B2 (en) 2008-12-10 2014-06-10 Glaxosmithkline Llc Pharmaceutical compositions
US20120148586A1 (en) 2009-08-27 2012-06-14 Joyce Ching Tsu Chou Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders
WO2011043530A1 (ko) 2009-10-09 2011-04-14 (주)알테오젠 Ｇｌｐ-1 유사체의 융합체, 및 이를 유효성분으로 함유하는 당뇨병의 예방 또는 치료용 조성물
US8389689B2 (en) 2009-10-28 2013-03-05 Janssen Biotech, Inc. Anti-GLP-1R antibodies and their uses
EP2496249B1 (en) 2009-11-03 2016-03-09 Amylin Pharmaceuticals, LLC Glp-1 receptor agonist for use in treating obstructive sleep apnea
WO2014037373A1 (en) 2012-09-07 2014-03-13 Sanofi Fusion proteins for treating a metabolic syndrome
SG10201704716XA (en) 2013-01-17 2017-07-28 Vtv Therapeutics Llc Combinations Of A GLP1R Agonist And Metformin And Use Thereof For The Treatment Of Type 2 Diabetes And Other Disorders
US20150259416A1 (en) 2014-03-12 2015-09-17 Biocrine Ab Methods for treating and/or limiting development of diabetes
CN104371019B (zh) * 2013-08-13 2019-09-10 鸿运华宁（杭州）生物医药有限公司 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质
CN104098702B (zh) * 2014-07-23 2017-06-16 湖北工业大学 一种利用mfh融合蛋白制备glp‑1多肽或其类似物方法和应用
CN106390100B (zh) * 2015-01-28 2021-06-22 中国科学院天津工业生物技术研究所 一种多肽复合物作为glp-1药物载体的应用、方法及其融合蛋白复合物
PL3257524T3 (pl) 2015-02-11 2021-03-08 Gmax Biopharm Llc Stabilny preparat farmaceutyczny w postaci roztworu białka fuzyjnego przeciwciała przeciwko glp-1r
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
AU2017277594A1 (en) * 2016-06-09 2019-02-07 Medimmune Limited Protease-resistant mono-lipidated peptides
MY200364A (en) 2017-09-22 2023-12-21 Regeneron Pharma Glucagon-like peptide 1 receptor agonists and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
（"The N-terminal alanine-extended GLP-1/IgG-Fc fusion protein confers resistance to DPP-IV and reduces serum glucose level in db/db mice";Hye-Shin Chung等;《Regulatory Peptides》;20110527;参见摘要，第2页左栏第1段-第4页左栏第1段 *

Also Published As

Publication number Publication date
US20240024428A1 (en) 2024-01-25
IL304574B2 (en) 2025-08-01
EA202090649A1 (ru) 2020-06-29
AU2018338178B2 (en) 2023-06-08
US20190091296A1 (en) 2019-03-28
AU2018338178A1 (en) 2020-04-02
US11779633B2 (en) 2023-10-10
AU2023223010A1 (en) 2023-11-09
CN111108117A (zh) 2020-05-05
IL273253B2 (en) 2024-07-01
US20210283225A1 (en) 2021-09-16
MY200364A (en) 2023-12-21
IL273253B1 (en) 2024-03-01
EP3684793A1 (en) 2020-07-29
US12090193B2 (en) 2024-09-17
ZA202001167B (en) 2024-06-26
CA3073964A1 (en) 2019-03-28
CN118955732A (zh) 2024-11-15
IL273253A (en) 2020-04-30
MY207828A (en) 2025-03-21
JP2020534016A (ja) 2020-11-26
WO2019060653A1 (en) 2019-03-28
JP7239566B2 (ja) 2023-03-14
IL304574A (en) 2023-09-01
KR20200054303A (ko) 2020-05-19
JP7559112B2 (ja) 2024-10-01
JP7789871B2 (ja) 2025-12-22
IL304574B1 (en) 2025-04-01
KR102696518B1 (ko) 2024-08-21
US11045522B2 (en) 2021-06-29
JP2024178255A (ja) 2024-12-24
MX2020002977A (es) 2020-11-06
AU2023223010B2 (en) 2025-12-04
US20250000949A1 (en) 2025-01-02
JP2023071827A (ja) 2023-05-23
SG11202001637PA (en) 2020-03-30

Similar Documents

Publication Publication Date Title
CN111108117B (zh) 胰高血糖素样肽1受体激动剂及其用途
EP3570885B1 (en) Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr)
JP7420730B2 (ja) 代謝機能不全または低レプチン血症の治療に使用するためのレプチン受容体アゴニスト性抗体
EP4353250A2 (en) Method of treating or ameliorating metabolic disorders using antagonistic binding proteins for gastric inhibitory peptide receptor (gipr)/glp-1 receptor agonist fusion proteins
CA3044249A1 (en) Methods of treating obesity with anti-angptl8 antibodies
JP2020524658A (ja) 胃抑制ペプチド受容体（ｇｉｐｒ）に対する結合タンパク質をｇｌｐ−１アゴニストと組み合わせて使用する、代謝障害の治療方法又は寛解方法
CN105801705A (zh) 含胰高血糖素样肽-1和免疫球蛋白杂合Fc的融合多肽及其用途
US12122817B2 (en) Long-lasting GLP1 analogue drug for type-2 diabetes
WO2025180387A1 (en) Super long-lasting glp1 or glp1/gip analogue drugfor type-2 diabetes and obesity
IL270267B1 (en) Methods of treating eye disorders with aplnr antagonists and vegf inhibitors
EA045412B1 (ru) Агонисты рецептора глюкагоноподобного пептида 1 и их применения
WO2025178928A1 (en) Combination therapy for the treatment of obesity
HK40120203A (en) Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr)
HK40017935A (en) Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr)
HK40017935B (en) Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr)
RU2019126781A (ru) Белки, связывающие глюкагоновые рецепторы, и способы их применения

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment
TG01 Patent term adjustment